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Extra-hepatic portal vein obstruction (EHPVO) is the
cause in majority of cases of portal hypertension (PH) in
children. It is usually idiopathic and is also reported
following umbilical vessel catheterisation in infancy or
biliary atresia surgery. Currently, medical and repetitive
sclerotherapy is the recommended management of
portal hypertension. However, up to 15% of children may
require shunt surgery. Shunt surgery offers one-time
solution to recurrent GI bleeding and hypersplenism.1
However, in pediatric age the procedure is technically
demanding due to small calibre veins. This study
evaluates indications, morbidity and patency of DSRS in
children with portal hypertension.
After ERC (ethical review committee) approval (2019-
0749-2321), medical records of pediatric patients
(<18 years) who had DSRS from January 1995 to
December 2018 at The Aga Khan University Hospital,
Karachi (Pakistan) were reviewed for patient demo-
graphics, indication of procedure, imaging, laboratory
investigations, operative time, morbidity, hospital stay,
shunt patency and episodes of recurrent bleeding.
Outcomes measures were prevention from repeat
bleeding episodes and improvement in platelet counts.
Data was analysed in SPSS version 22. Quantitative
variables were reported as means and/or medians.
Frequency was reported for categorical variables.
Difference in outcome variables were assessed through
paired t-test.
Median age of nine patients was 11 (6-16) years. Most
were males (6:3). All patients had history of upper
gastrointestinal bleeding including 4 (44.4%) patients
having multiple episodes. Median sclerotherapy sessions
before shunt procedures were 2 (0-4). All patients had
normal liver function tests. The procedures were
performed under general anaesthesia through trans-
verse upper abdominal incision. The splenic vein was
mobilised from its junction with superior mesenteric vein
to a length which can easily be brought to the left renal
vein to create a tension-free and supple end-to-side
anastomosis. The mean operative time was 263 ±22.2
minutes. Routine postoperative monitoring and care
was provided. There were no operative complications
including bleeding, injury to the surrounding structures,
wound infection, or encephalopathy. The mean hospital
stay was 8.8 ±1.26 days. Patients were followed three
monthly during first postoperative year and then
annually, both clinically and with ultrasound doppler.
Graft was considered patent if it showed flow from portal
venous system to renal vein.
Median follow-up was 3 (1-10) years. Mean preoperative
platelets improved from 57.3 ±22.2 to 94.3 ±34.4 X 109/l
(p=0.005) and splenic size decreased from 15.6 ±2.39 to
15.03 ±2.46 cm (p=0.692, Table I). Most patients (88.8%)
had no GI bleeding episode. One patient had bleeding 6
months after the surgery which required a session of
sclerotherapy. Shunts were patent on last follow-up
except in one patient whose shunt was noted to be
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Table I: Comparison of pre- and post-outcome parameters.
Variables Preoperative Postoperative p-value
Mean ± (SD) Mean ± (SD)
Bleeding episodes 9 (100%) 1 (11.1%) <0.001
Platelets count (x 109 / l) 57.4 ±22.2 94.4 ±34.4 0.005
Spleen size (cm) 15.6 ±2.4 15.1 ±2.5 0.692
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blocked at 6-month follow-up. She had protein C and S
deficiency and had small calibre vein (4 mm) and
dissection was difficult due to the previous episode of
pancreatitis. Another patient required splenectomy, two
years after the procedure for persistent hypersplenism
(low platelets and increasing transfusion requirements to
maintain hemoglobin levels).
EHPVO (extra-hepatic portal vein obstruction) is usually
the cause of portal hypertension in children and it
manifests with hematemesis and hypersplenism. Most
patients are treated with repeated sclerotherapy and
pharmacotherapy such as propranolol. In cases, which
are refractory to endoscopic treatment, DSRS is a
preferable alternative as it provides efficient and long-
lasting decompression of the portal venous system. The
reported cases of children managed with DSRS illustrate
that it is effective in preventing recurrent bleeding and
resolution of hypersplenism; and can safely be offered in
a developing country where access to medical care is
suboptimal. However, we observed that shunt surgery
should not be offered in children with previous history of
severe pancreatitis or hypercoagulable state.
There are several misconceptions about shunt surgery
in pediatric age group, e.g. high failure rates in children
under 10 years, particularly those whose veins are less
than 10 mm in diameter. The other is that bleeding
episodes in such children should be managed
conservatively until they grow out of the disease by
development of collateral circulation. There is no long-
term data to support these impressions.2
Many studies have demonstrated that shunts can
successfully be offered to children of any age with
minimal morbidity as success rate around 90%, as is
reported in different series.3 Orloff et al. have reported
97% patency and thrombosis in less than 5% of
patients.4 Similarly, Laurtz et al. reported remarkable
outcome in terms of prevention of recurrent GI
bleeding.5 Recently, Paloma et al. and Patel et al. have
shown effectiveness of DSRS in children.1,6 Moreover,
shunts are cost-effective, psychologically less traumatic
than the repeated endoscopic procedures, and favour
normal physical growth in children.
In conclusion, though this is a retrospective study from a
single centre with a small number of patients, it
demonstrates that shunt surgery is safe and reliable
alternative to repeated endoscopic procedures; for
prevention of bleeding and to improve hypersplenism in
children with extrahepatic portal hypertension.
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